Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials.

DocumentFichier
Fichier pdf chargé le 04/02/2015 à 17:58:01
Accès libre
(version auteur)
fichier
TitreUse of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials.
Type de publicationArticle de revue
AuteurMabilleau, Guillaume , Mieczkowska, Aleksandra , Chappard, Daniel
EditeurWiley
TypeArticle scientifique dans une revue à comité de lecture
Année2014
LangueAnglais
Date2014 May
Pagination260-6
Volume6
Titre de la revueJ Diabetes
ISSN1753-0407
Mots-clésbone fracture, GLP-1RA, glucagon-like peptide-1 receptor agonist, meta-analysis
Résumé en anglais

BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) are at a higher risk of bone fractures independent of the use of antidiabetic medications. Furthermore, antidiabetic medications could directly affect bone metabolism. Recently, the use of dipeptidyl peptidase-4 inhibitors has been associated with a lower rate of bone fracture. The aim of the present meta-analysis was to assess whether patients with T2DM treated with glucagon-like peptide-1 receptor agonists (GLP-1Ra) present a lower incidence of bone fracture compared with patients using other antidiabetic drugs.

METHODS: A search on Medline, Embase, and http://www.clinicaltrials.gov, as well as a manual search for randomized clinical trials of T2DM treated with either a GLP-1Ra or another antidiabetic drug for a duration of ≥24 weeks was conducted by two authors (GM, AM) independently.

RESULTS: Although 28 eligible studies were identified, only seven trials reported the occurrence of at least a bone fracture in one arm of the trial. The total number of fractures was 19 (13 and six with GLP-1Ra and comparator, respectively). The pooled Mantel-Haenszel odds ratio for GLP-1Ra was 0.75 (95% confidence interval 0.28-2.02, P = 0.569) in trials versus other antidiabetic agents.

CONCLUSIONS: Although preliminary, our study highlighted that the use of GLP-1Ra does not modify the risk of bone fracture in T2DM compared with the use of other antidiabetic medications.

URL de la noticehttp://okina.univ-angers.fr/publications/ua3449
DOI10.1111/1753-0407.12102
Autre titreJ Diabetes
Identifiant (ID) PubMed24164867